Fragasso Group Inc. Has $1 Million Position in Pfizer Inc. (NYSE:PFE)

Fragasso Group Inc. trimmed its holdings in shares of Pfizer Inc. (NYSE:PFEFree Report) by 3.5% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 36,161 shares of the biopharmaceutical company’s stock after selling 1,321 shares during the quarter. Fragasso Group Inc.’s holdings in Pfizer were worth $1,003,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. GoalVest Advisory LLC raised its stake in shares of Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares during the period. Creekmur Asset Management LLC bought a new stake in shares of Pfizer in the fourth quarter worth $32,000. VisionPoint Advisory Group LLC grew its position in Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares in the last quarter. Tennessee Valley Asset Management Partners bought a new position in shares of Pfizer in the 4th quarter valued at about $36,000. Finally, DiNuzzo Private Wealth Inc. acquired a new stake in shares of Pfizer in the fourth quarter valued at about $37,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Pfizer stock opened at $27.75 on Friday. The stock has a fifty day moving average of $27.67 and a 200-day moving average of $27.72. The stock has a market capitalization of $157.22 billion, a P/E ratio of -462.34, a price-to-earnings-growth ratio of 1.09 and a beta of 0.70. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $38.99.

Pfizer (NYSE:PFEGet Free Report) last announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.56 by $0.26. The company had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The firm’s revenue was down 19.5% on a year-over-year basis. During the same period in the previous year, the firm posted $1.23 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 14th. Shareholders of record on Friday, May 10th were given a $0.42 dividend. The ex-dividend date of this dividend was Thursday, May 9th. This represents a $1.68 annualized dividend and a yield of 6.06%. Pfizer’s dividend payout ratio is presently -2,799.53%.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of recent analyst reports. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Monday, June 17th. BMO Capital Markets reiterated an “outperform” rating and issued a $36.00 target price (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Morgan Stanley boosted their price target on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Guggenheim began coverage on Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Finally, Argus cut Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Ten equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $35.86.

Check Out Our Latest Stock Report on PFE

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Read More

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.